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Introduction: Acute grade 3 and 4 toxicity is commonly reported in trials examining altered 
fractionation radiotherapy (AFRT), due to its impact on treatment tolerance, the potential for 
consequential late effects, and mortality. Less well described is the mild-moderate acute toxicity 
and its impact on function. This study aims to examine acute toxicity and patient-reported side 
effects, and how they impact on function during AFRT. 
Study Design: A prospective cohort design study. 
Materials and Methods: Thirteen patients with T1-T3 oropharyngeal SCC were assessed weekly 
during, and at four weeks post-AFRT. Acute toxicity was graded using the CTCAE, and patients 
attended speech pathology/dietetic reviews where they reported functional barriers. Swallowing 
and weight measures were recorded. 
Results: Most participants experienced peak grade 2 toxicity for all CTCAE components, except 
laryngeal edema. Grade 3 mucositis and dysphagia was noted in 31% and 23% respectively. Peak 
toxicity occurred in week 5 of treatment; however barriers to oral intake occurred from week 1. 
Modified diet with supplementation was required for 92% by week 3. Participants lost 5 kg during 
treatment. By four weeks post-treatment acute toxicity was resolving, with ongoing diet 
modification and weight loss. 
Conclusion: Mild-moderate acute toxicity impacted on functional swallowing and weight from 
weeks 1-2, with increasing severity by week 3, before patients commenced their twice daily 
“concomitant boost” treatments. As acute toxicity resolved, the impact on oral intake and weight 
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continued. Future studies should record toxicity and barriers to oral intake routinely until its 
resolution, rather than at arbitrary time points post-treatment.  
Key words: acute toxicity, oropharyngeal cancer, altered fractionation radiotherapy, swallowing, 
nutrition. 
Introduction 
The benefits with regards to survival and 
locoregional control in treating locally 
advanced head and neck squamous cell 
carcinoma with altered fractionation 
radiotherapy (AFRT) have been well-
recognized [1]. One type of AFRT uses a 
concomitant boost (AFRT-CB) regimen which 
involves the delivery of a smaller second daily 
dose in the final days/weeks of treatment, and 
has been found to have significantly worse 
acute toxicity when compared with 
conventionally fractionated radiotherapy [2]. 
This fractionation protocol is being examined 
further in a prospective phase II TROG clinical 
trial (registered number: A0031029V). Patient-
reported side effects and their impact on 
functional outcomes during AFRT treatment 
have not been described extensively. 
Most reports of toxicity following 
radiotherapy treatment have focused primarily 
on grade 3 and 4 adverse events due to the 
impact such severe toxicity has on treatment 
completion, compliance and mortality. Severe 
acute toxicity has been associated with 
treatment breaks, weight loss, alternative 
feeding and hospitalization [3-6]. Studies within 
the last decade however have largely reported a 
pattern of reduced incidence of grade 3 and 4 
acute toxicity following concomitant boost 
protocols, with literature finding that between 
20-32% developed grade 3 or 4 dysphasia 
toxicity and 35-47% developing grade 3 or 4 
mucositis [2, 7-9]. However, in comparison, 
there has been less consistent reporting of 
mild-moderate acute toxicity following 
concomitant boost radiotherapy. Where data 
has been reported, it has revealed that the large 
majority of patients developed grade 1 or 2 
acute toxicity for erythema (68-85%) [2, 7, 9], 
xerostomia (67-100%) [2, 7-9], mucositis (40-
80%) [2, 7-9], and dysphasia (42-68%) [2,7,9], 
although no study has reported the clinical 
progression of when toxicity begins and at what 
stage it reaches maximal severity. Also less 
discussed in the literature to date is the 
functional impact of mild-moderate acute 
toxicity on functional swallowing and 
nutritional status. The challenges of toxicity 
reporting have been noted previously and 
include a lack of documented standards and 
poor consensus regarding reporting [10]. This 
limits the current understanding of the onset, 
progression, duration, and recovery from acute 
toxicity.  
Information regarding the pattern of acute 
toxicity, as well as patient-reported side effects 
of treatment is critical to assist service planning 
in relation to the nature and extent of speech 
pathology and dietetics support required by 
this population during and early after 
treatment. This paper aimed to: 1) 
prospectively examine the full range of early 
toxicity weekly during treatment to determine 
the onset and progression of acute toxicity; 2) 
determine the patterns of presentation and the 
peak severity and incidence of acute toxicity; 
and 3) describe the patient-reported barriers to 
oral intake and how they impact on functional 
swallowing and weight in patients with T1-T3 
locally advanced head and neck squamous cell 
carcinoma of the oropharynx treated with 
AFRT-CB.  
 
Material and Methods 
Participants 
Patients with a diagnosis of T1, T2, or T3N0 
SCC of the oropharynx (tonsil, base of tongue, 
pharyngeal wall or supraglottis [within 1cm of 
the oropharynx]) who presented to the Princess 
Alexandra Hospital Multidisciplinary Head and 
Neck Clinic in Brisbane, Australia between 
November 2006 and August 2009, and were 
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Figure 1 Percentage of AFRT-CB patients with acute toxicity as scored by CTCAE v.3 over time 
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treated with AFRT-CB, were eligible for 
recruitment. HPV p16 status was not reliably 
reported during this time at our institution, and 
thus is unknown in the investigated cohort. 
Ineligible patients included those with previous 
diagnosis of head and neck cancer, neurological 
or neurodegenerative condition that may have 
affected oral intake. All patients received their 
treatment at the Metro South Radiation 
Oncology Service in Brisbane, Australia. This 
research was approved by the Human Research 
and Ethics Committees at the Princess 
Alexandra Hospital, Australia, and the 
University of Queensland, which conform to the 
provisions under the Declaration of Helsinki. All 
participants provided written consent prior to 
involvement in the study. 
AFRT-CB was the recommended treatment 
for 17 patients during the study period, all of 
whom were eligible for recruitment. Two 
patients declined to participate, leaving a 
cohort of 15 participants who consented to 
involvement. Of these participants, complete 
data on 13 participants was available; one 
participant’s data set was incomplete as a result 
of death unrelated to cancer and another 
excluded due to inadequate attendance for 
weekly progress sessions.  
Participants were predominantly male (11 
male, 2 female) with a mean age of 67 years (SD 
= 9.02; range = 53-82). Demographic and 
clinical characteristics are reported in Table 1. 
The majority of participants had tonsillar (n = 8, 
62%) and supraglottic (within 1cm of the 
oropharynx; n = 3, 23%) primary disease. Fifty-
four percent of the participants had T2 tumours 
and the majority of patients (69%) had no 
nodal disease (N0). The majority of participants 
had stage III (39%) or stage II disease (31%). 
More than half (54%) of the participants were 
ex-smokers, 23% current smokers, and 85% 
reported being current alcohol drinkers. Prior 
to treatment mean weight of the cohort was 
83kg (SD = 23.63). 
Planned Treatment 
Patients received a total radiotherapy dose 
of 66Gy in 35 fractions over 5 weeks. All 
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Table 1: Demographics of AFRT-CB cohort at presentation 
Participant 
Number 
Age 
(years) 
Sex* TNM 
Classification† 
Stage Smoking Alcohol Weight 
(kgs) 
01 82 M T1N0 left 
pharyngeal wall 
I Ex Current 70.3 
02 63 M T2N0 supraglottic II Current Current 77.8 
03 79 M T3N0 BOT III Ex Current 74.5 
04 72 M T2N0 left tonsil II Never Current 75.2 
05 69 F T2N2b left tonsil IV Ex N/A 73 
06 73 M T2N0 left tonsil II Ex Ex 61 
07 70 M T1N0 left tonsil I Ex Current 106.7 
08 69 M T2N1 right tonsil III Ex Current 65.8 
09 69 M T3N0 right 
supraglottic 
III Current Current 81 
10 59 M T2N0 right 
supraglottic 
II Ex Current 81 
11 58 F T3N0 right tonsil III Current Current 59.5 
12 53 M T2N1 right tonsil III Never Current 142 
13 54 M T1N2a right tonsil IV Never Current 113 
* M = male, F = female. †T = T stage, N = N stage. 
 
 
Figure 2: Pattern of most common patient-reported barriers to 
oral intake during AFRT-CB treatment 
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patients were treated with 3D conformal 
radiotherapy using curative intent AFRT-CB. 
Elective sites were treated to 50Gy in 2Gy/day 
over 5 weeks. Known sites of disease received a 
concomitant boost schedule to a total of 66Gy 
over 5 weeks with an 
afternoon boost dose 
(minimum of 6 hours 
apart) of 1.6Gy/day in 
weeks 4 and 5.  
Outcome Measures 
Participants were 
examined prospectively 
each week during 
treatment (week 1 to 5) 
with a further follow-up 
assessment at four weeks 
following completion of 
treatment. Table 2 outlines 
the assessment schedule 
and outcome measures 
used by each professional. 
At each time point, the 
radiation oncologist scored 
treatment toxicity using the 
CTCAE v.3 [11]. Toxicity was recorded in each 
participant’s medical chart during the review 
appointment with their treating radiation 
oncologist.   
In addition, at each time point participants 
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Table 2: Assessment schedule for radiation oncologist, speech pathologist, and dietitian during 
treatment and at four weeks post-AFRT-CB 
Outcome Measure Time point 
 Pre Wk§ 1 Wk2 Wk3 Wk 4 Wk5 4wks 
post 
Radiation Oncology Assessment: 
     CTCAE v.3* 
     Symptom management 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Speech Pathology Assessment:  
     CSE† 
     Oral cavity examination 
     Recommendations‡ re:  
Dry mouth/thick secretions 
Odynophagia 
Trismus 
Oral ulceration 
Oral candidiasis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dietitian Assessment:  
     Weight 
     Diet history 
     Supplements/alternative feeding 
     Recommendations‡ re: 
Anorexia 
Dysgeusia 
Nausea/ vomiting 
Diarrhoea 
Constipation 
Dysosmia 
Early satiety 
Timely access to food 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Common Toxicity Criteria for Adverse Events version 3.0. †Clinical swallow examination. ‡Recommendations and 
symptom management provided in conjunction with multidisciplinary team. §Wk/s = week/weeks. 
underwent combined speech pathology and 
dietetic review assessments. Rather than 
speech pathology and dietetic involvement 
occurring reactively in response to swallowing 
difficulties or weight loss, routine intervention 
was provided on a weekly basis during 
treatment. In the speech pathology assessment, 
participants were interviewed and asked to 
report the side effects that they perceived were 
barriers to their oral intake. They also 
underwent a clinical swallow examination to 
determine the tolerance and safety of diet and 
fluid consistencies, examination of the oral 
cavity, and recommendations regarding oral 
cares and strategies to manage barriers to oral 
intake (Table 2). The dietitian completed 
assessment of weight, diet history, prescription 
and monitoring of nutritional supplements 
nd/or alternative feeding and 
recommendations to manage barriers 
impacting on oral intake (Table 2). Symptom 
management was provided in conjunction with 
the multidisciplinary team.  
Statistical analysis 
All data was recorded on a set “Swallowing 
and Nutrition Proforma” to ensure consistent 
reporting and then entered into an Excel 
spreadsheet. Data were entered into Stata v.10 
for Mac. Analysis was by intention-to-treat; 
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Figure 3 Pattern of diet and nutritional supplementation for AFRT-CB participants during and at 
4 weeks post-treatment 
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Table 3: Peak incidence of toxicity at any stage during AFRT-CB 
Toxicity Grade 3 Grade 2 Grade 1 No 
toxicity 
Erythema 15% 39% 39% 8% 
Xerostomia 0% 77% 23% 0% 
Dysphagia 23% 62% 15% 0% 
Laryngeal edema 0% 15% 31% 54% 
Mucositis 31% 62% 0% 8% 
 
therefore, if a patient missed one review 
appointment, but not consecutive 
appointments, the last observations obtained 
from the participant were carried forward as 
the missing observations, with the aim of 
optimizing analysis and reducing bias 
associated with missing data [12]. During the 
course of data collection, six participants 
missed scheduled follow-up appointments and 
required one set of imputed data (over weeks 
2-5) only. Descriptive statistics were used to 
explore weekly toxicity levels and patient-
reported barriers to oral intake. Non-
parametric correlations (Spearman rho) were 
conducted to determine associations between 
weekly toxicity scores and toxicity in week 5 of 
treatment. One-way 
repeated-measures ANOVA 
was used to record change 
over time points with ratio 
data (weight), with 
repeated-measures t tests 
used for post-hoc 
comparisons. For all 
statistical comparisons, p < 
0.05 was taken to indicate 
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Table 4: Percentage of patients receiving AFRT-CB who reported listed side effects as barriers to 
oral intake  
Patient-reported 
side effect 
% reporting 
side effect at 
week 1 
% reporting 
side effect at 
week 2 
% reporting 
side effect at 
week 3 
% reporting 
side effect at 
week 4 
% reporting 
side effect at 
week 5 
Fatigue -* - 8 8 - 
Anorexia 15 23 31 39 54 
Dysgeusia - 54 54 62 77 
Early satiety - - - - 8 
Nausea - - 8 8 23 
Vomiting - - - 15 8 
Diarrhoea - 15 23 8 - 
Constipation - - 8 8 31 
Candidiasis 8 8 15 8 8 
Ulceration 8 - 39 31 39 
Odynophagia 23 69 92 100 100 
Xerostomia 31 85 39 69 85 
Trismus - - 8 8 8 
*– refers to no patient reporting the listed side effect 
statistical significance. 
Result 
Toxicity severity during treatment 
All participants experienced levels of 
toxicity of grade 1 or higher during treatment. 
For the majority of participants, peak toxicity 
was rated as grade 2 in severity (Table 3). The 
highest incidence of grade 3 toxicity was 
observed for mucositis, with small numbers of 
participants reported to have grade 3 toxicity 
for dysphasia and erythema (Table 3). No 
patient developed grade 3 acute toxicity for 
xerostomia or laryngeal edema, and no patients 
developed grade 4 toxicity. 
Patterns of acute toxicity 
The toxicity profile of participants from 
week 1 to four weeks post-treatment is 
reported in Figure 1. The onset of acute toxicity 
occurred in week 1. Except for laryngeal edema 
and erythema, the majority of participants had 
developed grade 1 or 2 toxicity by week 2. The 
first recording of grade 3 toxicity was found for 
mucositis at week 1 (8%), dysphasia at week 2 
(8%), and erythema at week 5 (14%). The 
highest incidence and severity across acute 
toxicities was found in week 5, with peak 
incidence and severity evident for dysphagia, 
xerostomia, and mucositis. All patients had 
developed salivary changes by week 5. 
Recovery from acute toxicity had begun by four 
weeks post-treatment, with both severity and 
incidence reduced compared with week 5 of 
treatment across all toxicities scored.  
Correlations between overall toxicity scores 
from weeks 1-4 and week 5 revealed no 
relationship between the toxicity profile at 
week 1 and toxicity at week 5 ( = 0.05, p = 
0.71). In comparison, significant but moderate 
correlations were found for toxicity levels 
between week 2 and 5 ( = 0.34, p = 0.004), 
week 3 and 5 ( = 0.58, p < 0.001) and week 4 
and 5 ( = 0.66, p < 0.01).  
Barriers to oral intake 
During treatment, patients reported 
odynophagia, xerostomia, dysgeusia, anorexia, 
and oral ulceration as the most common 
barriers to oral intake, ranging in peak 
incidence from 39 -100% of the group (Table 
4). The number of perceived barriers increased 
as treatment progressed, with the onset of 
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reporting as early as weeks 1 and 2 of 
treatment (Figure 2). Week 3, however, was the 
time point when the incidence of patient-
reported barriers to oral intake increased 
considerably (Table 4). In week 4, with the 
onset of twice daily fractions, 100% reported 
odynophagia, and two thirds reported taste 
alterations and xerostomia as barriers to oral 
intake. In week 5, odynophagia remained a 
concern for all with peak incidence for anorexia, 
dysgeusia, early satiety, nausea, constipation, 
oral ulceration, and xerostomia also observed at 
this time.  
Impact on functional swallowing and weight 
Diet and fluid tolerance followed a similar 
pattern to clinician-rated dysphagia toxicity. 
Almost all participants required a modified diet 
with oral supplementation by week 3 as a result 
of toxicity and reported barriers to oral intake 
(Figure 3). Between week 3 and week 5, only 
one patient was able to tolerate a full diet and 
thin fluids, and by week 5 two patients required 
nasogastric tube insertion due to toxicity and 
concerns regarding aspiration. In week 5, two 
participants on modified diets with 
recommendations for oral supplementation 
were unable to tolerate the supplements due to 
oral burning/pain on consumption, and 
therefore were restricted to a modified diet 
only. On average, mean LOW for the cohort was 
5kg during treatment, and a further 5kg 
between treatment completion and 1 month 
post-treatment, although this was not 
significant (F = 0.38, p = 0.89). Mean weight for 
the cohort at four weeks post-treatment was 
73kg (SD = 18.56). 
Discussion 
Previous reports have documented small 
numbers (1-14%) of patients developed acute 
grade 4 toxicity following AFRT-CB [2, 7] 
however none were recorded in the current 
cohort. Levels of grade 3 dysphagia and 
mucositis toxicity for the current cohort was 
similar to previously reported for rates of 
dysphagia toxicity (20-29%) and slightly less 
than that for mucositis (35-47%) [2, 7-9]. The 
majority of the current cohort developed mild-
moderate toxicity similar to previous reports 
[9, 8, 7, 2], except for dysphasia. Grade 1 or 2 
dysphasia toxicity has previously ranged from 
42-68%, however in our cohort 77% developed 
grade 1 or 2 dysphasia toxicity.  
The progression of acute toxicity following 
an AFRT-CB cohort has not yet been fully 
reported. From week 2, the toxicity profile 
correlated with toxicity at week 5 of treatment, 
indicating a relationship between early onset 
toxicity and the progression of toxicity in the 
final week of treatment. Knowledge of this 
relationship may assist clinicians to better 
educate patients regarding the course of their 
toxicity, as well as foresee potential need for 
supportive care in the end stages of treatment. 
Other accelerated fractionation regimens have 
found acute toxicity occurred earlier with 
greater severity when compared to 
conventional fractionation [13-15]. Our peak 
incidence for mucositis of 92% at week 5 is 
higher and occurred later than that found for 
patients who received a continuously hyper 
fractionated accelerated radiotherapy (CHART) 
regimen [15]. The current data were not 
dissimilar to reports of conventional treatment 
where peak toxicity occurred in the final 2 
weeks of treatment in 85% of patients[16]. It is 
also possible that some individuals may have 
experienced a further increase in acute toxicity 
beyond week 5 of treatment, as some have 
reported that the most severe toxicity following 
AFRT occurred 5-7 weeks from the 
commencement of treatment [16, 14]. Although 
the current study did not follow participants 
beyond week 5, this potential for further 
deterioration must be acknowledged. 
Clinician-rated toxicity provides an overall 
summary of the tolerance of radiotherapy 
treatment, however there is growing interest in 
the patient-experience and impact on function 
during and following treatment. Patient-
reported barriers to oral intake were first 
recorded in weeks 1 and 2 in the current 
cohort, with the onset of mild to moderate 
dysphasia, xerostomia, and mucosal toxicity. 
Both clinician-rated toxicity and patient-
reported barriers of odynophagia, xerostomia, 
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dyspepsia, anorexia, and oral ulceration led to 
negative functional consequences with 
modifications to diet occurring for nearly 50% 
of participants in week 2, and 92% in week 3. 
Saunders et al. [15] found a larger proportion of 
patients undergoing a CHART treatment 
protocol described early (week 3) dysphasia 
and odynophagia, requiring analgesia, 
compared with patients receiving conventional 
treatment. However no comment was made 
regarding oral intake, need for nutritional 
supplementation, or nutritional outcomes. In 
the current cohort, similar to Saunders et al. 
[15], week 3 marked the increase of reported 
barriers to oral intake, and this co-occurred 
with 92% patients requiring a modified diet or 
nasogastric feeding. This result supports the 
need for early symptom management, 
swallowing and nutritional intervention. 
The peak incidence for patient-reported 
barriers to oral intake occurred at week 5, 
however, similar to toxicity, it could be possible 
that the incidence of barriers to oral intake may 
continue to increase in the early weeks post-
treatment. Supportive intervention from speech 
pathology and dietetics between treatment 
completions until four weeks post-treatment 
varied, due to patient need or clinical follow-up 
being determined by local centers. The few 
authors who have reported weekly assessment 
of toxicity until peak toxicity subsided did not 
comment regarding return to oral intake and 
weight maintenance [9, 6]. It is therefore 
difficult to extrapolate whether regular follow-
up early post-treatment resulted in improved 
functional outcomes in these studies. Perhaps 
reduced support via contact with health 
professionals in the early post-treatment phase 
explains the continued weight loss post-
treatment in the current cohort. These results 
suggest that the provision of supportive 
intervention for AFRT-CB patients needs to 
occur routinely pre-treatment, and on a weekly 
basis until the resolution of side effects, to 
ensure the barriers to oral intake are minimized 
and negative nutritional sequelae are avoided. 
Conclusion 
This is the first exploration of the pattern of 
onset and progression of early toxicity, patient-
reported barriers to oral intake, functional 
swallowing, and weight in a cohort of 
oropharyngeal patients treated with AFRT-CB. 
Our findings suggest that mild-moderate 
toxicity impacting on oral intake begins in 
weeks 1 and 2 of treatment, with increasing 
severity and incidence by week 3 of treatment, 
prior to patients commencing their twice daily 
“concomitant boost” treatments. The most 
severe toxicity was observed in the final week 
of treatment and it is possible, that for some, 
severe toxicity may have continued into the 
post-treatment phase. The requirement of a 
modified diet and weight loss continues for the 
majority of patients at four weeks post-
treatment despite improvement in acute 
toxicity. The limitations of this research are 
recognized and include small participant 
numbers limiting the generalizability of our 
results and a single time point post-treatment 
record of toxicity, rather than regular 
assessment to accurately record resolution of 
acute toxicity in the early post-treatment phase. 
Future research needs to examine the 
resolution of acute toxicity and barriers with a 
routine approach. Additionally, clinicians 
grading acute toxicity and providing supportive 
care should be aware of the patient-perspective 
regarding their treatment experience. The 
reporting of barriers to oral intake undoubtedly 
relates to patient motivation, compliance, and 
family support; a topic requiring exploration in 
future studies. 
Learning Points 
1. Mild to moderate acute toxicity 
associated with altered fractionation 
radiotherapy impacts on swallowing 
and nutrition from week one of 
treatment. 
2. A modified diet and nutritional 
supplementation is required by almost 
all patients receiving altered 
fractionation radiotherapy by week 3 of 
treatment, and is required for several 
weeks following treatment. 
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3. Patient-reported barriers to oral intake 
add a valuable insight to assist with 
providing supportive care to patients 
through altered fractionation 
radiotherapy. 
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